Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol [Phase 1, Phase 2]
This clinical trial update describes a continuation protocol for ZEN003694 in patients with metastatic castration-resistant prostate cancer …
-
CLINICAL_TRIALS withdrawal · 2025-03-12Clinical Trial Update: Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
Clinical trial update reports real-world Brazilian experience in castration-resistant prostate cancer patients treated with the combination …
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of HC-1119 Soft Capsules in metastatic castration-resistant prostate cancer is c…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
Geode Therapeutics is conducting a Phase 1 study of GT-220F for metastatic castration-resistant prostate cancer, currently not yet recruitin…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
This completed trial compares changes in tumor burden using 68Ga-PSMA-11 PET/CT versus 177Lu-PSMA SPECT/CT in metastatic castration-resistan…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
This clinical trial update reports the completion of a study assessing the usefulness of 18F-FDG PET/CT in patients with metastatic castrati…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC [Phase 1, Phase 2]
A Phase 1/2 trial evaluating EPI-7386 in combination with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
This clinical trial update shows Kuopio University Hospital is recruiting for a Lutetium-177-PSMA study in PSMA PET-positive metastatic pros…
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This clinical trial update reports results from a Phase 1 study evaluating the combination of Lutetium-177-PSMA-617 and pembrolizumab in pat…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
This clinical trial update reports that the Phase 1 study of HRS-5041 in metastatic castration-resistant prostate cancer is currently recrui…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) [Phase 1]
Poseida Therapeutics conducted a Phase 1 trial of P-PSMA-101 CAR-T cells in metastatic castration-resistant prostate cancer and advanced sal…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study
This completed prospective multicenter Swiss registry study assesses the performance of 177Lu-PSMA-I&T radioligand therapy for metastatic ca…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer [EARLY_Phase 1]
A Phase 1 clinical trial update from Sichuan University reports safety, whole-body distribution, and radiation dosimetry data in patients wi…
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
This entry describes a Phase 1/2 trial to assess safety, tolerability, and preliminary efficacy of 161Tb-NYM032 in metastatic castration-res…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 1]
AC176, an investigational therapy, in a Phase 1 study for metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
This clinical trial update reports on survival outcomes for metastatic castration-resistant prostate cancer in Brazil, analyzing patient cha…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
A clinical trial evaluating the PARP inhibitor olaparib for castration-resistant prostate cancer, including patients with BRCA mutations; cu…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies [Phase 2]
This clinical trial update reports on a Phase 2 study of XmAb20717 (Vudalimab) in selected advanced gynecologic and genitourinary cancers, w…
-
CLINICAL_TRIALS other · 2025-02-07Clinical Trial Update: Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Clinical trial update on a Phase 1/Phase 2 study combining Radium-223 with Lutetium-177 PSMA-I&T for metastatic castration-resistant prostat…
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer [NA]
Completed single-center, single-arm study evaluating the safety and efficacy of the radiopharmaceutical 177Lu-LNC1011 in PSMA PET-positive m…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 1]
Phase 1 safety and immunogenicity results for JNJ-64041809, a live attenuated Listeria-based immunotherapy, in metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]
The Phase 1 trial evaluating EPI-7386 in combination with abiraterone acetate plus prednisone or with apalutamide in metastatic castration-r…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A clinical trial registry entry for Janssen's prospective compliance registry in metastatic castration-resistant prostate cancer has been wi…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy [Phase 4]
Completed Phase 4 clinical trial evaluating abiraterone acetate in metastatic castration-resistant prostate cancer patients who had a poor r…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
A post-marketing safety study of abiraterone acetate (Zytiga) in Indian participants with metastatic castration-resistant prostate cancer ha…